Xenon Pharmaceuticals has been granted a patent for a method of treating anhedonia in humans by administering Compound A. The compound has shown promise in addressing this condition, with improved methods of therapy and administration also covered in the patent. GlobalData’s report on Xenon Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Xenon Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Xenon Pharmaceuticals's grant share as of May 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of anhedonia using compound a
A recently granted patent (Publication Number: US11957675B2) outlines a method for treating anhedonia, a condition characterized by the inability to experience pleasure, by administering a compound known as Compound A to individuals in need of treatment. Compound A, identified as N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide, is used to reverse hyperactivity in the ventral tegmental area (VTA) in individuals suffering from anhedonia. The method involves enhancing the opening of specific potassium channels, such as Kv7.2, Kv7.3, Kv7.4, or Kv7.5, selectively over Kv7.1, to address symptoms of anhedonia, including sexual and social anhedonia.
Furthermore, the patent details the application of Compound A in treating various neuropsychiatric disorders, including depressive disorders like stress-induced depression, major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and substance-related disorders such as dependency on alcohol, cocaine, opioids, or nicotine. The method also extends to conditions like schizophrenia, Alzheimer's disease, epilepsy, chronic pain, and other neurological disorders. Compound A is administered at varying doses ranging from 2 to 200 mg, with specific dosages tailored to individual needs, and can be orally administered before or after meals. The severity of anhedonia, measured using the Snaith-Hamilton Pleasure Scale (SHAPS), serves as a benchmark for determining the effectiveness of the treatment, with a minimum severity level required for initiating Compound A therapy.
To know more about GlobalData’s detailed insights on Xenon Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
